Incidence
  Mortality

Prostate Cancer
Estimated Incidence, Mortality and Prevalence Worldwide in 2012

Estimated numbers (thousands)CasesDeaths5-year prev. 
 World10953073858 
 More developed regions7421422871 
 Less developed regions353165987 
 WHO Africa region (AFRO)5237135 
 WHO Americas region (PAHO)413851539 
 WHO East Mediterranean region (EMRO)191247 
 WHO Europe region (EURO)4201011513 
 WHO South-East Asia region (SEARO)3925123 
 WHO Western Pacific region (WPRO)15346499 
 IARC membership (24 countries)7911572998 
 United States of America23330980 
 China4723104 
 India191264 
 European Union (EU-28)345721277 
  

Estimated age-standardised rates (World) per 100,000
   At a glance

Prostate cancer is the fourth most common cancer in both sexes combined and the second most common cancer in men. An estimated 1.1 million men worldwide were diagnosed with prostate cancer in 2012, accounting for 15% of the cancers diagnosed in men, with almost 70% of the cases (759,000) occurring in more developed regions. Prostate cancer incidence varies more than 25-fold worldwide; the rates are highest in Australia/New Zealand and Northern America (ASR 111.6 and 97.2 per 100,000, respectively), and in Western and Northern Europe, because the practice of prostate specific antigen (PSA) testing and subsequent biopsy has become widespread in those regions. Incidence rates are also relatively high in certain less developed regions such as the Caribbean (79.8), Southern Africa (61.8) and South America (60.1), but remain low in Asian populations with estimated rates of 10.5 and 4.5 in Eastern and South-Central Asia.

With an estimated 307,000 deaths in 2012, prostate cancer is the fifth leading cause of death from cancer in men (6.6% of the total men deaths). Because PSA testing has a much greater effect on incidence than on mortality, there is less variation in mortality rates worldwide (ten-fold from approximately 3 to 30 per 100,000) than is observed for incidence, with the number of deaths from prostate cancer larger in less developed than in more developed regions (165,000 and 142,000, respectively). Mortality rates are generally high in predominantly black populations (Caribbean, 29 per 100,000 and sub-Saharan Africa, ASRs 19-24 per 100,000), very low in Asia (2.9 per 100,000 in South-Central Asia for example) and intermediate in the Americas and Oceania.
  
GLOBOCAN 2012 (IARC) , Section of Cancer Surveillance (2/12/2016)

Estimated Prostate Cancer Incidence Worldwide in 2012
Estimated age-standardised rates (World) per 100,000

 Trends in incidence of prostate cancer in selected countries: age-standardised rate (W) per 100,000
*Regional data *Regional data *Regional data
NORDCAN (www.ancr.nu)
ECO (eco.iarc.fr)
England: www.ons.gov.uk
CI5.iarc.fr CI5.iarc.fr
Australia: www.aihw.gov.au
New Zealand: www.health.govt.nz
USA: seer.cancer.gov
GLOBOCAN 2012 (IARC) , Section of Cancer Surveillance (2/12/2016)

Estimated Prostate Cancer Mortality Worldwide in 2012
Estimated age-standardised rates (World) per 100,000

 Trends in mortality from prostate cancer in selected countries: age-standardised rate (W) per 100,000
WHO (www.who.int/healthinfo/en/) WHO (www.who.int/healthinfo/en/) WHO (www.who.int/healthinfo/en/)